ChemoCentryx

$56.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.67 (-1.17%) As of 7:20 PM UTC today

Why Robinhood?

You can buy or sell ChemoCentryx and other stocks, options, and ETFs commission-free!

About CCXI

ChemoCentryx, Inc. Common Stock, also called ChemoCentryx, is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA. The listed name for CCXI is ChemoCentryx, Inc. Common Stock.

CEO
Thomas J. Schall
Employees
82
Headquarters
Mountain View, California
Founded
1996
Market Cap
4.28B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
584.19K
High Today
$59.23
Low Today
$56.30
Open Price
$57.38
Volume
225.62K
52 Week High
$70.29
52 Week Low
$30.72

CCXI News

BenzingaMar 1

ChemoCentryx: Q4 Earnings Insights

Shares of ChemoCentryx (NASDAQ:CCXI) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 65.

CCXI Earnings

-$0.43
-$0.19
$0.05
$0.29
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.33 per share
Actual
-$0.43 per share
Replay Earnings Call

You May Also Like

DWFI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure